Kyowa Kirin Co., Ltd. (4151.T) Bundle
A Brief History of Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd., founded in 1949, began as a manufacturer of pharmaceuticals in Japan. The company is headquartered in Tokyo and has established itself as a key player in the biopharmaceutical industry. Initially known for its focus on traditional pharmaceuticals, Kyowa Kirin has shifted its focus towards biotechnology and innovative medicines.
In the early 2000s, Kyowa Kirin made strategic acquisitions to enhance its R&D capabilities. Notably, in 2008, the company acquired Kirin Pharmaceutical Company, which played a significant role in expanding its product portfolio. This merger brought together traditional drug development with advanced biopharmaceutical capabilities.
Kyowa Kirin's commitment to research and development is reflected in its substantial investment figures. In 2022, the company reported R&D expenditures of approximately ¥52.5 billion, representing about 18% of its total sales. Such investments have positioned the company to successfully launch various innovative therapies.
One of the major milestones in Kyowa Kirin's history was the approval of its leading drug, Nesp (darbepoetin alfa), in 2007, which showcased the company’s capacity to develop effective biotech medications for anemia associated with chronic kidney disease. In 2020, Nesp generated sales of over ¥50 billion, solidifying its position as a cornerstone of the company's revenue.
In addition to its flagship products, Kyowa Kirin has expanded into oncology and immunology. The launch of Crysvita (burosumab) in 2018, for the treatment of X-linked hypophosphatemia, has been a key revenue driver. By 2021, Crysvita sales were reported at approximately ¥22 billion, highlighting the company’s growth in rare disease therapies.
The table below summarizes key financial data for Kyowa Kirin's fiscal year 2022, illustrating the company's performance in various segments.
| Segment | Revenue (¥ billion) | Percentage of Total Revenue |
|---|---|---|
| Oncology | 45.0 | 16.8% |
| Nephrology | 60.0 | 22.4% |
| Immunology | 30.0 | 11.2% |
| Other Pharmaceuticals | 130.0 | 48.6% |
Kyowa Kirin has also focused on international expansion, establishing a presence in various global markets, including the United States and Europe. By 2022, international sales accounted for around 35% of total revenue, reflecting the success of its global strategy.
As of October 2023, Kyowa Kirin's market capitalization stands at approximately ¥900 billion, signaling a robust demand for its innovative product line. The company’s stock performance has varied, with a year-to-date increase of approximately 15%, indicative of investor confidence in its future prospects and growth trajectory.
Overall, the evolution of Kyowa Kirin Co., Ltd. showcases its transition from a local pharmaceutical manufacturer to a significant player in the global biopharmaceutical market, driven by strategic acquisitions, strong R&D investments, and a clear focus on innovative therapies.
A Who Owns Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd., a global biotechnology company headquartered in Tokyo, Japan, operates primarily in the pharmaceutical industry. The ownership structure of Kyowa Kirin is notably diverse, with significant stakes held by various institutional and individual investors.
Major Shareholders:| Shareholder | Stake (%) | Type |
|---|---|---|
| The Master Trust Bank of Japan, Ltd. (Trust Account) | 8.90 | Institutional Investor |
| Japan Trustee Services Bank, Ltd. (Trust Account) | 6.32 | Institutional Investor |
| JP Morgan Chase Bank, N.A. | 5.37 | Institutional Investor |
| State Street Bank and Trust Company | 4.55 | Institutional Investor |
| Nomura Asset Management Co., Ltd. | 4.05 | Institutional Investor |
| Individual and Other Investors | 70.81 | Individual Shareholders |
As of the latest report in October 2023, these percentages illustrate the distribution of ownership, with institutional investors holding a notable combined stake of approximately 29.19%.
Kyowa Kirin has seen fluctuations in its stock price, which was approximately ¥2,093 per share in October 2023. The company’s market capitalization stands at around ¥515.1 billion (approximately $4.57 billion USD), reflecting its position within the biotechnology sector.
Recent Financial Performance:For the fiscal year ending December 2022, Kyowa Kirin reported total revenues of approximately ¥280.4 billion (around $2.52 billion USD), with a net income of ¥42.3 billion (approximately $380 million USD). The earnings per share (EPS) stood at ¥215.32.
In the first half of 2023, the company posted revenue of ¥122.5 billion (around $1.1 billion USD), representing a 12.3% increase year-over-year, driven by strong sales in its biologics division.
Kyowa Kirin’s commitment to research and development is evident, with R&D expenditures reaching ¥45 billion (approximately $410 million USD) in 2022, constituting about 16.0% of its total revenues.
According to data from Bloomberg, the company's stock is listed on the Tokyo Stock Exchange under the ticker symbol 4151.T, and its stock price performance year-to-date shows approximately a 15.2% increase.
Overall, the ownership landscape of Kyowa Kirin is primarily shaped by a mix of institutional and individual investors, reflecting the company's appeal in the biopharmaceutical market.
Kyowa Kirin Co., Ltd. Mission Statement
Kyowa Kirin Co., Ltd. is a global specialty pharmaceutical company dedicated to advancing the health and well-being of people worldwide. The company focuses on the research, development, manufacture, and sale of highly innovative pharmaceutical products aimed at addressing unmet medical needs.
The company's mission statement emphasizes a commitment to creating new value for society through innovative pharmaceutical advancements. Kyowa Kirin aims to maximize patient benefit while ensuring sustainable growth and operational excellence. Detail-oriented, the firm aligns its objectives with stakeholder expectations, including patients, healthcare professionals, and shareholders.
As of its latest fiscal report, Kyowa Kirin achieved net sales of ¥456.3 billion for the fiscal year ending December 2022. This reflects a strong growth rate of 12% compared to the previous fiscal year. The company reported an operating profit of ¥54.1 billion, with a **margin of 11.8%**. The net income attributable to the shareholders was approximately ¥38.3 billion, demonstrating robust business performance.
Kyowa Kirin has positioned itself in specific therapeutic areas, particularly in oncology, immunology, and nephrology. In the oncology segment, for example, sales have surged significantly, contributing to a total of ¥150 billion. This represents a year-over-year growth of 25% as the company expands its product offerings in response to growing market demand.
Additionally, Kyowa Kirin aims to foster a culture of innovation and collaboration. The company invests nearly **20%** of its revenue into R&D, focusing on cutting-edge biotechnology and novel drug discovery. In the latest fiscal year, R&D expenses reached ¥91.2 billion, emphasizing its commitment to developing transformative therapies.
| Metric | Fiscal Year 2022 | Growth Rate (%) |
|---|---|---|
| Net Sales | ¥456.3 billion | 12% |
| Operating Profit | ¥54.1 billion | 11.8% margin |
| Net Income | ¥38.3 billion | N/A |
| Oncology Sales | ¥150 billion | 25% |
| R&D Expenses | ¥91.2 billion | 20% of revenue |
Kyowa Kirin is also committed to sustainability and social responsibility, actively participating in initiatives that enhance community health and welfare. This focus is evident in the company's efforts to reduce its carbon footprint, aiming for a **30% reduction** in greenhouse gas emissions by 2030, compared to 2020 levels.
The corporate governance structure of Kyowa Kirin reflects its mission-driven ethos. The company established a diverse Board of Directors to drive strategic decisions, ensuring alignment with its long-term objectives. In the latest analysis, **30%** of board members are women, showcasing a commitment to diversity and inclusion.
In summary, Kyowa Kirin’s mission statement encapsulates its dedication to innovation and societal contribution through its pharmaceutical advancements. Coupled with strong financial performance, the company is well-positioned to continue making a significant impact on global health outcomes.
How Kyowa Kirin Co., Ltd. Works
Kyowa Kirin Co., Ltd., a global biopharmaceutical company based in Japan, operates primarily in the field of pharmaceuticals. Its core business focuses on innovative drug discovery and development, particularly in therapeutic areas such as oncology, nephrology, and immunology.
The company is part of the broader healthcare sector and is noted for its commitment to research and development (R&D). For the fiscal year ended December 2022, Kyowa Kirin reported R&D expenses amounting to ¥56.2 billion, representing approximately 19% of its total sales.
Business Segments
- Prescription Pharmaceuticals: This segment contributed significantly to Kyowa Kirin's revenue, generating ¥280 billion in sales for 2022.
- Over-the-Counter (OTC) Pharmaceuticals: While a smaller portion compared to prescription drugs, OTC sales were around ¥25 billion in 2022.
Kyowa Kirin's key products include:
- Onoctocog alfa (ELOCTATE®): A treatment for hemophilia A.
- Benlysta®: Used for systemic lupus erythematosus.
- Brentuximab vedotin (ADCETRIS®): An antibody-drug conjugate used for specific types of lymphoma.
Financial Performance
As of the end of 2022, Kyowa Kirin reported consolidated revenue of ¥295 billion, marking an increase of 11.5% from the previous year.
| Financial Metric | 2021 (¥ billion) | 2022 (¥ billion) | Change (%) |
|---|---|---|---|
| Revenue | 265 | 295 | 11.5 |
| Operating Income | 46 | 50 | 8.7 |
| Net Income | 32 | 36 | 12.5 |
| R&D Expenses | 50 | 56.2 | 12.4 |
Market Presence
Kyowa Kirin has expanded its global reach, with a presence in over 30 countries. Its strategic acquisitions and partnerships bolster its market position, including collaborations with major pharmaceutical companies for co-developing products. In 2022, the company entered a partnership with Regeneron Pharmaceuticals to advance the development of new therapies.
Stock Performance
Kyowa Kirin is publicly traded on the Tokyo Stock Exchange under the ticker symbol 4151. As of October 2023, its stock was priced at approximately ¥3,250, reflecting a year-to-date increase of 15%. The company has a market capitalization of about ¥650 billion.
- P/E Ratio: 22.5
- Dividend Yield: 2.0%
Future Outlook
Looking ahead, Kyowa Kirin aims to introduce several new drugs, with 10 candidates currently in clinical trials. The company expects to launch up to three new products by 2025, focusing primarily on oncology and rare diseases.
In summary, Kyowa Kirin Co., Ltd. operates through its robust pharmaceutical business model, emphasizing R&D and global expansion, which are pivotal for its sustained growth trajectory.
How Kyowa Kirin Co., Ltd. Makes Money
Kyowa Kirin Co., Ltd., a biopharmaceutical company based in Japan, primarily generates revenue through the development and commercialization of innovative pharmaceuticals. Its revenue streams are diversified across multiple therapeutic areas, including oncology, nephrology, and immunology.
Revenue Breakdown
- Pharmaceutical sales: ¥359.3 billion (FY 2022)
- Research and development: ¥75.1 billion (FY 2022)
- Licensing and royalties: ¥18.5 billion (FY 2022)
Key Products
Kyowa Kirin's flagship products include:
- Omalizumab (Xolair): Used for allergic asthma, contributing ¥70.2 billion in sales in FY 2022.
- Bremelanotide (Vyleesi): An injectable treatment for hypoactive sexual desire disorder in women, generating ¥11.6 billion in FY 2022.
- Gadobutrol (Gadovist): A contrast agent for magnetic resonance imaging, accounting for ¥15.4 billion in sales in FY 2022.
Distribution Channels
Kyowa Kirin utilizes a multi-faceted distribution strategy, which includes:
- Direct sales to healthcare providers
- Partnerships with major pharmaceutical companies
- Global licensing agreements
Financial Performance
| Year | Total Revenue (¥ billion) | Operating Income (¥ billion) | Net Income (¥ billion) | R&D Expenses (¥ billion) |
|---|---|---|---|---|
| 2020 | ¥319.5 | ¥39.8 | ¥28.4 | ¥67.0 |
| 2021 | ¥337.2 | ¥45.1 | ¥31.5 | ¥72.3 |
| 2022 | ¥359.3 | ¥54.9 | ¥38.2 | ¥75.1 |
Market Trends and Growth Drivers
The biopharmaceutical market is witnessing significant growth, driven by:
- Increased investment in R&D, with a projected CAGR of 8.5% through 2026.
- Rising demand for personalized medicine and biologics.
- Strategic acquisitions and partnerships to enhance product pipelines and market reach.
Recent Developments
Kyowa Kirin continues to innovate and expand its global footprint through recent initiatives:
- Acquisition of Vividion Therapeutics for $1.2 billion to bolster its oncology portfolio.
- Strategic collaboration with Regeneron Pharmaceuticals in 2022, focusing on antibody-based therapies.
Overall, Kyowa Kirin's diverse revenue streams, strategic growth initiatives, and robust product pipeline position it favorably in the competitive biopharmaceutical landscape.
Kyowa Kirin Co., Ltd. (4151.T) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.